ProCE Banner Activity

Abemaciclib + Endocrine or HER2-Targeted Therapies in Metastatic Breast Cancer

Slideset Download
Conference Coverage
Abemaciclib combined with endocrine or HER2-targeted therapies was safe and active in patients with MBC.

Released: December 18, 2015

Expiration: December 16, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation